Thank you for your follow-up comment for CMS117v12, Childhood Immunization Status.
We apologize for the inconvenience this may have caused. Unfortunately, the value sets, once published, cannot be revised. The publication policies and timelines for the MIPS program are determined by the Centers for Medicare & Medicaid Services (CMS). The Advisory Committee on Immunization Practices (ACIP) approved recommendations for the use of 20-valent pneumococcal conjugate vaccine (PCV20) for children, and these recommendations were adopted by the CDC Director on June 27, 2023. This date falls after the value set publication dates for 2023 and 2024 performance periods, on May 5, 2022 and May 4, 2023 respectively. Upon this discovery, the eCQM team created a known issue for Performance Period 2023 (CMS117v11) and 2024 (CMS117v12) implementations
EKI-27 acknowledges that the value set does not include CVX codes 216, for PCV20. A workaround, specifically mapping to existing codes in the value set (CVX code 152 or unspecified CVX code 216) is included. Specifically, the recommendation for the known issue states:
“Implementers can map the use of 20-valent pneumococcal conjugate vaccine (PCV20) (CVX code 216) to the ‘pneumococcal vaccine, unspecified formulation’ code (CVX code 216) or the ‘Pneumococcal Conjugate, unspecified formulation’ code (CVX code 152) in the 'Pneumococcal Conjugate Vaccine' (OID: 2.16.840.1.113883.3.464.1003.196.12.1221) value set.”
The value set used for the Performance Period 2025 implementation of CMS117v13 (published 2024.05.02) has since been updated to include PCV20 (CVX code 216) for use in PY2025 reporting. We regret any inconvenience this may have caused.